TY  -  
T1  - Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment : Is There Still Hope? 
SN  -  /  
UR  - http://hdl.handle.net/10138/333884 
T3  -  
A1  - Hyytiäinen, Aini; Wahbi, Wafa; Väyrynen, Otto; Saarilahti, Kauko; Karihtala, Peeter; Salo, Tuula; Al-Samadi, Ahmed 
A2  -  
PB  -  
Y1  - 2021 
LA  - eng 
AB  - Background Head and neck squamous cell carcinoma (HNSCC) carries poor survival outcomes despite recent progress in cancer treatment in general. Angiogenesis is crucial for tumour survival and progression. Therefore, several agents targeting the pathways that mediate angiogenesis have been developed. We conducted a systematic review to summarise the current clinical trial data examining angiogenesis inhibitors in HNSCC. Methods We carried out a literature search on three angiogenesis inhibitor ca... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - anti-angiogenesis; head and neck cancer; therapy; endostatin; bevacizumab; PHASE-II-TRIAL; ADVANCED NASOPHARYNGEAL CARCINOMA; RECOMBINANT HUMAN ENDOSTATIN; AND/OR METASTATIC HEAD; LOCALLY ADVANCED HEAD; RADIATION-THERAPY; CONCURRENT CHEMORADIATION; HEPATOCELLULAR-CARCINOMA; TARGETING ANGIOGENESIS; TUMOR ANGIOGENESIS; 3122 Cancers 
N1  -   
PP  -  
ER  -